Cytokinetics, Incorporated (CYTK) P/E Ratio History
Deep ValueTrading at -12.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2009–2016
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, Cytokinetics, Incorporated (CYTK) trades at a price-to-earnings ratio of -12.0x, with a stock price of $78.78 and trailing twelve-month earnings per share of $-6.73.
The current P/E is 177% below its 5-year average of 15.7x. Over the past five years, CYTK's P/E has ranged from a low of 6.7x to a high of 40.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CYTK trades at a 154% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.
Relative to the broader market, CYTK trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CYTK DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CYTK Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CYTK P/E vs Peers
Neuroscience and Psychiatry Therapies peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $10B | 50.9 | -Best | +128%Best | |
| $4B | 9.4Lowest | -Best | +68% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CYTK Historical P/E Data (2009–2016)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2016 Q4 | Dec 31 2016 | $12.15 | $0.30 | 40.5x | +157% |
| FY2010 Q1 | Mar 31 2010 | $19.20 | $2.68 | 7.2x | -54% |
| FY2009 Q4 | - | $17.46 | $2.62 | 6.7x | -58% |
| FY2009 Q3 | Sep 30 2009 | $31.74 | $2.57 | 12.4x | -22% |
| FY2009 Q2 | - | $16.98 | $1.41 | 12.0x | -24% |
Average P/E for displayed period: 15.7x
Full Stock Analysis
Deep dive into CYTK consensus models and risk factors.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CYTK — Frequently Asked Questions
Quick answers to the most common questions about buying CYTK stock.
What is CYTK's P/E ratio?
Cytokinetics, Incorporated (CYTK) trailing twelve-month P/E ratio is -12.0x, based on TTM diluted EPS of $-6.73. The 5-year average P/E is 15.7x and the historical range spans 6.7x to 40.5x.
Is CYTK stock overvalued or undervalued?
CYTK trades at -12.0x P/E, below its 5-year average of 15.7x. At the 0th percentile of its historical range (6.7x–40.5x), the stock is priced at a discount to its own history.
Is CYTK stock expensive?
No, CYTK is not expensive on a historical basis. The current P/E of -12.0x is below the 5-year average of 15.7x and sits at the 0th percentile of its valuation range.
What is CYTK's historical P/E range?
Over the past 5 years, CYTK's P/E ratio has ranged from 6.7x to 40.5x, with a median of 12.0x and an average of 15.7x. The current P/E of -12.0x places the stock at the 0th percentile of this range. Full historical data spans 2009–2016.
How does CYTK's P/E compare to the S&P 500?
CYTK trades at -12.0x P/E versus the S&P 500 median of 24.4x. The 149% discount to the market suggests lower growth expectations or perceived higher risk.
How does CYTK's valuation compare to Healthcare peers?
Cytokinetics, Incorporated P/E of -12.0x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CYTK's PEG ratio?
CYTK PEG ratio is N/A, based on a P/E of -12.0x and EPS growth of -24.3%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CYTK's earnings yield?
CYTK earnings yield is N/A, the inverse of its -12.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.